• Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study

  NCT06792448

  Not yet recruitingObservationalUpdated Jan 30, 2025
• INS, B Cells and Microbiota

  NCT04924712

  RecruitingObservationalUpdated Mar 3, 2026
• SLIT ABS: Study on Patients With Autoimmune Podocytopathy

  NCT07516964

  RecruitingInterventionalNot ApplicableUpdated Apr 8, 2026
• Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE

  NCT03592030

  Unknown statusObservationalUpdated Jul 19, 2018
• A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.

  NCT04207580

  RecruitingObservationalUpdated Mar 13, 2026
• Steroid Treatment of Idiopathic Nephrotic Syndrome

  NCT01386957

  CompletedObservationalUpdated Jul 20, 2021

ClinicalTrials.gov ID

NCT04174066

Lead Sponsor

Centre Hospitalier Universitaire de NiceOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

144Estimated

Last Update Posted

Jun 22, 2026Actual

Start Date

May 20, 2020Actual

Primary Completion Date

May 20, 2031Estimated

Completion Date

May 20, 2031Estimated

Official Title

From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With Minimal Glomerular Injury Nephrotic Syndrome (MGLS) and Primary Segmental and Focal Hyalinosis (HSFP)

Brief Summary

Idiopathic Nephrotic Syndrome (INS) is a kidney disease characterized by massive proteinuria and hypoalbuminemia. It includes two anatomopathological entities: nephrotic syndrome with minimal glomerular lesions (SNLGM) and primary segmental and focal hyalinosis (PHF). Renal biopsy reveals a fusion of the feet of the podocytes without inflammatory lesions or deposits of immune complexes. Clinical and experimental observations strongly suggest that the immune system and podocyte dysfunction are the two facets of the disease. There are currently no clinical or biological markers to predict the diagnosis of corticosteroid sensitivity, corticosteroid dependence, or risk of recurrence of kidney disease after kidney transplantation. To our knowledge, no prospective studies have been designed to study both immune system alterations and podocyte damage as well as genetic predisposition variants in NIS. Therefore, the use of steroids/immunosuppressive agents is purely empirical with a multitude of side effects.

The objective is to identify and test new therapeutic targets rather than conducting new trials with existing treatments, using either drug candidates or molecules selected by high throughput screening of libraries of repositioning molecules using an appropriate read-out. The biobank may also be used to analyze the effects of conventional treatments on identified new biomarkers. We expect the project to produce original and patentable results with subsequent valuation. Patentability will be anticipated before any publication on the subject. The patent and valorization cells of hospitals, INSERM and Universities will be involved in the results as soon as they are obtained.

• Nephrotic Syndrome

• blood sample
• tissue sample
• excreta

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• First episode of idiopathic nephrotic syndrome in a child aged 12 months to 18 years with a weight > 10 kg and biologically defined as proteinuria > 0.20 g / mmol creatinuria and hypoalbuminemia <25 g / mmol
• First episode of NIS defined in adults as albumin level <30 g / L and a urinary protein/creatinine ratio (UPCR) ≥ 300 mg / mmol systematically associated with the performance of a renal anatomopathological examination and characterized by the absence of identifiable lesions by light microscopy (SNLGM) or the presence of HSF lesions.
• For adults: signed informed consent to participate in the study
• For children: patients will be informed and a written informed consent form will be signed by both parents of the children at inclusion
• Patients affiliated to the French health system

Exclusion Criteria:

• Patients who have previously received corticosteroids and/or immunosuppressants
• Patients with reduced CH50 and/or low C3 and/or low C4 and/or low C4 (in some cases increased sC5b9 and/or presence of a C3 nephritic Factor; an anti-C3b...)
• SNLGM resulting from a secondary process (lymphoid hematopathies or neoplasia) or occurring following the administration of a treatment known to be associated with an SNLGM (lithium, interferon, non-steroidal anti-inflammatory drugs)
• Non-primary FHH (absence of Nephrotic Syndrome, etiological assessment revealing FHH secondary to an identified cause (genetic or not), no introduction of corticosteroids or immunosuppressants as first-line treatment)
• Positive serological screening test for HIV, hepatitis B or C
• Positive immunological tests for antinuclear and anti-DNA antibodies or anti-PLA2R1 and anti-THSD7A
• Patient under guardianship or curatorship

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Centre Hospitalier Universitaire de NiceOTHER

vincent.audard@aphp.fr(33)149814446